In the course of our screening for inhibitors of sphingosine kinase, we found an active compound from a culture broth of a discomycete, Trichopezizella barbata SANK25395. The structure of the compound, named F-12509A, was elucidated by a combination of spectroscopic analyses, to be a new sesquiterpene quinone consisting of a drimane moiety and a dihydroxybenzoquinone. Enzymekinetic analyses showed that F-12509A inhibits sphingosine kinase activity in a competitive manner with respect to sphingosine, with a Kt value of 1 8 /1M. (SPP) was initially described as an intermediate in the metabolic pathway of long-chain sphigoid basesl\ However, it is now widely accepted to be a unique bioactive lipid messenger2'^. SPP has been shown to be involved in a variety of cellular functions, including mediation of Fc£RI receptor signaling in mast cells4), nerve growth factor-mediated neuronal survival and differentiation5^regulation of cell motility6' 7), platelet activation8), activation of muscarinic K+currents9), neurite retraction10) and cell proliferation, especially in response to the stimulus of platelet-derived growth factor1 1 '12\ Sphingosine kinase, which catalyzes phosphorylation of sphingosine (SPH) on its primary hydroxyl group, is a key enzymethat regulates cellular SPP levels. Intervention of SPH kinase activity with specific inhibitors may give us some insight on the roles of SPP and SPH kinase in cellular physiology. Moreover, these inhibitors would have clinical value since SPP generation might be implicated in pathogenic states such as arteriosclerosis6'11}, thrombosis8'13), and inflammation4 
Results

Taxonomyof the Producing Organism
The F-12509A producing organism, SANK25395, was derived from a single ascospore discharged from a fresh apothecium occurring on an unidentified piece of wood collected in May, 1994 in Aomori Pref., Japan using a single-ascospore isolation technique. As this discomycete could not be identified by its properties in culture, the dried apothecia were examined for identification. The mycological properties were as follows (Fig. 2 ).
Apothecia were sessile to stipitate, globose or patelliform with incurving margin, grayish orange disc with brown hairs. Ectal excipulum was light to pale brown and twolayered; the outer layer was "textura angularis" to "textura globulosa", composed of cells of 5-8 /im across, whereas the inner layer was composed of closely interwoven, intricate hyphae of 2-3/im wide. Hairs were mostly straight, but often flexuous, undulate or strongly curved, multi-septate, up to 250 /im long, with walls 3-5^m thick.
The apices of the hairs were blunt, occasionally capped with resinous matter, rarely showing glandular expansion and up to 5/urn wide. Asci were 60-70.5X4.5-5/urn, cylindrical clavate, arising from croziers. Ascospores were 10-13X2-3/im, elliptic to fusiform and mostly single septate. Paraphyses were narrowly lanceolate, 3-3.5 ium thick at the widest point and exceeding the asci for 10- 
Isolation
The isolation procedure of F-12509A is summarized in Fig. 3 . The cultured broth (800ml) of Trichopezizella barbata SANK25395 was extracted with an equivalent volumeof acetone. The extract was concentrated in vacuo to removethe acetone, and the resulting aqueous solution was further extracted with ethyl acetate at pH 3.0. The ethyl acetate extract was washed with brine, dried over Na2SO4 Similar phenomenonhas been reported on stealthin A23). Therefore, F-12509A was treated with diazomethane and the 13C-NMRspectrum of the resulting dimethyl derivative showed all of the carbon signals as expected ( Table 2) . Analyses of the DQF-COSYand HMBCspectra of the dimethyl derivative suggested the existence of the 8(12)-drimene skeleton and NOESY data confirmed the relative configuration as shown in Fig. 4 . A literature search based on the partial structure hit two compounds, zonarol24) and hyatellaquinone25). The physico-chemical properties and spectral data of the dimethyl derivative and hyatellaquinone were very close except for the presence of a methoxygroup at 2' position in the former. Therefore the structure of the dimethyl derivative was decided to be 2'-O-methyl hyatellaquinone, and thus that of the original active compound, F-12509A, was proved as shown in Fig. 1 .
Enzyme Inhibitory Activities
To characterize the biological activities of F-12509A, we first examined the effect of F-12509A on SPH kinase activity in the cell-free system. In the subsequent experiments, we used DMSas a positive control, as it is a known competitive inhibitor of SPHkinase13). As shown in Fig. 5 , F-12509A inhibited rat liver SPH kinase in a dosedependent manner with an IC50 value of 18//M and it inhibited the enzyme completely at 50jiu. On the other hand, the dimethyl derivative of F-12509A showed only 30% inhibition even at 250jim. Kinetic analyses of F12509Awere performed using the rat liver cytosol fraction as the SPHkinase source. The increasing Kmvalues but no effect on the Vmaxvalue in the presence of increasing concentrations of F-12509A, shown in the LineweaverBurke plot (Fig. 6A) , indicate that the inhibition was competitive with respect to SPH. Moreover, the Dixon plot also indicates that F-12509A inhibited SPH kinase in a competitive manner with respect to SPH, with a Kt value of 18^M (Fig. 6B) In order to assess the specificity of F-12509A, we evaluated the effects of the compoundon other kinases (PI 3-kinase and PKC) and mammalian neutral SMase, a key enzyme of sphingolipid metabolism. F-12509A showed no inhibitory activity towards these enzymes at 100 jiM, which indicates that F-12509A is a specific inhibitor for SPH kinase. 
Discussion
A new compound, F-12509A is the first SPH kinase inhibitor isolated from natural sources, and not an analog of SPH. F-12509A inhibits rat liver SPH kinase in a dosedependent manner with the IC50 value of 18/xm and the inhibition is complete at 50^M (Fig. 5) . It also inhibits endogenous SPH kinase activity in platelets even when added extracellularly (Fig. 7) . This fact shows that F-12509A permeates the plasma membrane and inhibits SPH kinase even in intact cells. Moreover, F-12509A is a specific inhibitor for SPH kinase, since it shows no inhibitory activity towards other enzymes (i.e. neutral SMase, PI 3-kinase and PKC) even at IOO^m. Therefore, F-12509A may fit our requirement for the inhibition of SPH kinase to study the biological functions of SPP. Kinetic analyses of F-12509A show that the inhibition is competitive with respect to SPH (Fig. 6) . The results suggest that the sesquiterpene moiety of F-12509A may mimic the conformation of SPHin the binding to the active site of SPH kinase. Though we do not have muchevidences on the inhibitory mechanism of this compound, hydroxyl groups are necessary to inhibit SPH kinase since the inhibitory effect of the dimethyl derivative of F-12509A is significantly lower than that ofF-12509A (Fig. 5) . DMS, an analog of SPH, has been used as a potent inhibitor of SPH kinase. In practice, DMS had higher inhibitory activity than F-12509A as shown in Fig. 5 and Furthermore, it is reported that DMS can be phosphorylated in activated platelets26). Thus, application of this reagent should be made with great care. Accordingly, we still needed a new inhibitor of SPHkinase and screened for inhibitors of SPH kinase. Hence we isolated the novel and specific SPH kinase inhibitor, F-12509A. In summary, a new compound, F-12509A is the first SPH kinase inhibitor from natural sources that is not an analog of SPH. Therefore, it is hoped that F-12509A will be an effective tool to understand the role of SPP in the cellular physiological functions.
